Clint Dederick named CEO of AllTranz Inc.

Editor's note: AllTranz was founded by UK College of Pharmacy faculty researcher Audra Stinchcomb. The company is set to begin human clinical trials on a novel transdermal pain management product that will be used to treat osteoarthritis.

Lexington,KY (July 10, 2009) - Clint (Skip) Dederick has been named president and chief executive officer of AllTranz Inc. Founded in 2004, AllTranz is a specialty pharmaceutical company that is developing unique pain management products that deliver medication transdermally through patches and gels with reduced side effects and improved efficacy and patient compliance.

“AllTranz is pleased to have found a well-qualified CEO to pilot us through the current economic and regulatory environment. Skip has already put forward a creative three-tiered approach to financing and begun establishing strategic relationships,” said Audra Stinchcomb, chief scientific officer, AllTranz founder and UK College of Pharmacy faculty researcher.

Dederick brings more than 30 years of operational experience within the pharmaceutical, biotechnology and medical device sectors along with extensive venture capital experience. His career highlights include raising more than $120 million at Argos Therapeutics via venture capital and strategic alliances and $7 million as CEO of Nephrion, Inc. Beyond his duties as CEO of AllTranz, Dedreck is a board member of SpineForm LLC in Cincinnati, Ohio, representing Queen City Angels and Ft. Washington Capital Partners.